High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgenindependent prostate cancer cells

Oncotarget

Volumn 7, Issue 28, 2016, Pages 44492-44504

  Xie, Jinhan ^a,f   Mølck, Christina ^b   Paquet Fifield, Sophie ^b   Butler, Lisa ^c   Sloan, Erica ^a,d,e   Ventura, Sabatino ^a   Hollande, Frédéric ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Prostate cancer; Self renewal; Treatment resistance; TROP2

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; DOCETAXEL; FLUTAMIDE; PROTEIN; SMALL INTERFERING RNA; TROP2 PROTEIN; UNCLASSIFIED DRUG; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TAXOID; TUMOR ANTIGEN;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DOWN REGULATION; DRUG RESISTANCE; GLEASON SCORE; HUMAN; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER STEM CELL; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SCID MOUSE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION MOLECULES; CELL SURVIVAL; FLUTAMIDE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978766821     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9876     Document Type: Article

References (37)

1. Obertova Z, Brown C, Holmes M and Lawrenson R. Prostate cancer incidence and mortality in rural men-a systematic review of the literature. Rural Remote Health. 2012; 12:2039.
2. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ and Haas GP. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994; 8:439-443.
3. Trewartha D and Carter K. Advances in prostate cancer treatment. Nat Rev Drug Discov. 2013; 12:823-824.
4. Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J and Li Y. Cancer stem cells in prostate cancer chemoresistance. Curr Cancer Drug Targets. 2014; 14:225-240.
5. Liu C, Li Z, Bi L, Li K, Zhou B, Xu C, Huang J and Xu K. NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells. Mol Cell Biochem. 2014; 393:265-270.
6. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG and Reddy VA. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:268-273.
7. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O and Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumorinitiating cells in the Pten-null prostate cancer model. Cancer research. 2009; 69:8555-8562.
8. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L and Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006; 25:1696-1708.
9. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA and Jiang F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest. 2010; 90:234-244.
10. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA and Witte ON. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. The Prostate. 2010; 70:491-501.
11. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP and Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:20882-20887.
12. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J and Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes & development. 2012; 26:2271-2285.
13. Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A and Languino LR. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer research. 2013; 73:3155-3167.
14. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Pena JG and Trevino V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PloS one. 2013; 8:e74250.
15. Gulzar ZG, McKenney JK and Brooks JD. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene. 2013; 32:70-77.
16. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, KantoffPW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC medical genomics. 2010; 3:8.
17. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C and Shen MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461:495-500.
18. Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M and Spagnoli GC. Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clin Cancer Res. 2013; 19:5361-5371.
19. Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M, Piantelli M, Biganzoli E and Alberti S. Trop-2 is a determinant of breast cancer survival. PloS one. 2014; 9:e96993.
20. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Muller HM, Margreiter R, Ofner D and Fong D. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009; 62:152-158.
21. Ning S, Liang N, Liu B, Chen X, Pang Q and Xin T. TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci. 2013; 34:1745-1750.
22. Wirth MP and Froschermaier SE. The antiandrogen withdrawal syndrome. Urol Res. 1997; 25:S67-71.
23. Olea N, Sakabe K Fau-Soto AM, Soto Am Fau-Sonnenschein C and Sonnenschein C. The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology. 1990; 126:1457-1463.
24. Kai L and Levenson AS. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Res. 2011; 31:3323-3330.
25. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002; 277:26321-26326.
26. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375:1437-1446.
27. Jaworska D, Krol W and Szliszka E. Prostate Cancer Stem Cells: Research Advances. International journal of molecular sciences. 2015; 16:27433-27449.
28. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB and Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. British journal of cancer. 2008; 98:756-765.
29. Wang F, Liu X, Yang P, Guo L, Liu C, Li H, Long S, Shen Y and Wan H. Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis. Cell death & disease. 2014; 5:e1133.
30. Liu D, Cardillo TM, Wang Y, Rossi EA, Goldenberg DM and Chang CH. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. Molecular cancer. 2014; 13:53.
31. Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell. 2009; 4:203-205.
32. Kreso A and O'Brien CA. Colon cancer stem cells. Current protocols in stem cell biology. 2008; Chapter 3: Unit 3 1.
33. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B and Weinberg RA. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:7950-7955.
34. Ma I and Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011; 7:292-306.
35. Trerotola M, Li J, Alberti S and Languino LR. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the beta1 integrin-RACK1 axis. J Cell Physiol. 2012; 227:3670-3677.
36. Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV and Gurova KV. Prostate Cancer Cells Tolerate a Narrow Range of Androgen Receptor Expression and Activity. The Prostate. 2007; 67:1801-1815.
37. Hu Y and Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009; 347:70-78.